| Identification | Back Directory | [Name]
1H-Pyrazole-4-carboxamide, N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methyl- | [CAS]
2364554-48-1 | [Synonyms]
CK-274
Aficamten
Aficamten (CK-3773274
1H-Pyrazole-4-carboxamide, N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-
CK3773274,CK-3773274,cardiac,CK-274,Myosin,cardiomyopathy,Inhibitor,CK 3773274,CK 274,hypertrophic,inhibit,Aficamten,CK274,HCM | [Molecular Formula]
C18H19N5O2 | [MOL File]
2364554-48-1.mol | [Molecular Weight]
337.38 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 125 mg/mL (370.50 mM; Need ultrasonic) | [form ]
A crystalline solid | [pka]
13.84±0.20(Predicted) | [color ]
White to light brown |
| Hazard Information | Back Directory | [Uses]
Aficamten can be useful in the study of myosin modulation in cardiovascular medicine. | [in vivo]
Aficamten is a next-generation cardiac myosin inhibitor that provides a projected human half-life appropriate for once a day dosing, reaching steady state within two weeks, and demonstrates a wide therapeutic window in vivo with a clear PK/PD relationship[1].
Aficamten exhibits moderate oral bioavailability (mouse 98%, rat 55%, rat 58%,rat 79%, dog 45%, monkey 41%) following oral administration (mouse 1 mg/kg, rat 2 mg/kg, rat 3 mg/kg, rat 8 mg/kg, dog 1 mg/kg and monkey 1 mg/kg)[1].
Aficamten exhibits terminal elimination half-lives (mouse 4.5 h, rat 3.0 h, dog 33.8 h and, monkey 8.1 h) following intravenous administration (mouse 0.5 mg/kg, rat 1 mg/kg, dog 1 mg/kg and monkey 1.0 mg/kg)[1]. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|